Literature DB >> 32077602

Optimizing curative management of hepatocellular carcinoma.

Pierre Nahon1,2,3, Eric Vibert4, Jean-Charles Nault1,2,3, Nathalie Ganne-Carrié1,2,3, Marianne Ziol2,3,5, Olivier Seror2,3,6.   

Abstract

The goal of curative management of hepatocellular carcinoma is to provide the best chance of remission. However, recurrence rates for both local and distant relapse are high. Patient subgroups at higher risk of these events can be identified based on histological patterns that are closely linked to specific molecular subtypes. Patient outcome has improved with more effective therapeutic strategies thanks to technological advances in surgical techniques and percutaneous ablation. The main goal of controlling the cause of liver disease is to decrease distant/late recurrence and prevent deterioration of hepatic function. Ongoing trials testing the combination of neoadjuvant and/or adjuvant regimens with these procedures as well as routine tumour molecular analysis may modify therapeutic algorithms for hepatocellular carcinoma in the future.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ablation; adjuvant; biopsy sample; hepatocellular carcinoma; resection

Mesh:

Year:  2020        PMID: 32077602     DOI: 10.1111/liv.14345

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

Review 1.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

2.  Upregulation of ERCC6L is associated with tumor progression and unfavorable prognosis in hepatocellular carcinoma.

Authors:  Bin Yu; Han Liang; Qifa Ye; Yanfeng Wang
Journal:  J Gastrointest Oncol       Date:  2020-10

3.  The Effect of Encapsulated Apigenin Nanoparticles on HePG-2 Cells through Regulation of P53.

Authors:  Mayada Mohamed Mabrouk Zayed; Heba A Sahyon; Nemany A N Hanafy; Maged A El-Kemary
Journal:  Pharmaceutics       Date:  2022-05-29       Impact factor: 6.525

Review 4.  MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review.

Authors:  Mohanned Alnammi; Jeremy Wortman; Jaclyn Therrien; Jalil Afnan
Journal:  Abdom Radiol (NY)       Date:  2022-05-07

5.  The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma.

Authors:  Yaokai Ma; Guowei Liu; Jinzu Yang; Xin Li; Xiyi Yang; Shiming Fang; Baocheng Zhao
Journal:  Contrast Media Mol Imaging       Date:  2022-06-06       Impact factor: 3.009

6.  Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Authors:  Toulsie Ramtohul; Valérie Vilgrain; Olivier Soubrane; Mohamed Bouattour; Alain Luciani; Hicham Kobeiter; Sébastien Mule; Vania Tacher; Alexis Laurent; Giuliana Amaddeo; Hélène Regnault; Julie Bulsei; Jean-Charles Nault; Pierre Nahon; Isabelle Durand-Zaleski; Olivier Seror
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

7.  Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation.

Authors:  Hui Ma; Zhongchen Li; Jia Yuan; Lan Zhang; Xiaoying Xie; Xin Yin; Rongxin Chen; Zhenggang Ren
Journal:  Gastroenterol Res Pract       Date:  2021-01-02       Impact factor: 2.260

8.  Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review.

Authors:  Xing He; Yaorong Peng; Zhenyu Zhou; Wenbin Li
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

Review 9.  Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria.

Authors:  Yanzhao Zhou; Yi Yang; Bingyan Zhou; Zhengzheng Wang; Ruili Zhu; Xun Chen; Jingzhong Ouyang; Qingjun Li; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.